Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2293-2298

  Buckwold, Victor E ^a   Wei, Jiayi ^a   Wenzel Mathers, Michelle ^a   Russell, Julie ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS C VIRUS; IC 50; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CATTLE; CELL LINE; DIARRHEA VIRUSES, BOVINE VIRAL; DRUG SYNERGISM; HEPACIVIRUS; INTERFERON-ALPHA; RIBAVIRIN; VIRUS REPLICATION; YELLOW FEVER VIRUS;

EID: 0037974623     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2293-2298.2003     Document Type: Article

References (41)

1. Baginski, S. G., C. D. Pevear, M. Seipel, S. C. C. Sun, C. A. Benetatos, S. K. Chunduru, C. M. Rice, and M. S. Collett. 2000. Mechanism of action of a pestivirus antiviral compound. Proc. Natl. Acad. Sci. USA 97:7981-7986.
2. Bartenschlager, R., and V. Lohmann. 2001. Novel cell culture systems for the hepatitis C virus. Antivir. Res. 52:1-17.
3. Blight, K. J., A. Grakoui, H. L. Hanson, and C. M. Rice. 2002. The molecular biology of hepatitis C virus, p. 81-108. In J.-H. J. Ou (ed.), Hepatitis viruses. Kluwer Academic Publishers, Norwell, Mass.
4. Bodenheimer, H. C., Jr., K. L. Lindsay, G. L. Davis, J. H. Lewis, S. N. Thung, and L. B. Seef. 1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26:473-477.
5. Castet, V., C. Fournier, A. Soulier, R. Brillet, J. Coste, D. Larrey, D. Dhumneaux, P. Maurel, and J.-M. Pawlotsky. 2002. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J. Virol. 76:8189-8199.
6. Cheney, I. W., V. C. H. Lai, W. Zhong, T. Brodhag, S. Dempsey, C. Lim, Z. Hong, J. Y. N. Lau, and R. C. Tam. 2002. Comparative analysis of antihepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J. Virol. 76:11148-11154.
7. Contreras, A. M., Y. Hiasa, W. He, A. Terella, E. V. Schmidt, and R. T. Chung. 2002. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76:8505-8517.
8. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 98:6895-6900.
9. Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
10. Di Bisceglie, A. M., H. S. Conjeevaram, M. W. Fried, R. Sallie, Y. Park, C, Yurdaydin, M. Swain, D. E. Kleiner, K. Mahaney, and J. H. Hoofnagle. 1995. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123:897-903.
11. Dushieko, G., J. Main, H. Thomas, O. Reichard, C. Lee, A. Dhillon, S. Rassam, A. Fryden, H. Ressink, M. Bassendine, G. Norkrans, T. Cuypers, N. Lelie, P. Tefler, J. Watson, C. Sillikens, and O. Weiland. 1996. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25:591-598.
12. Frese, M., T. Pietschmann, D. Moradpour, O. Haller, and R. Bartenschlager. 2001. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82:723-733.
13. Glue, P., R. Rouzier-Panís, C. Raffanel. R. Sabo, S. K. Gupta, M. Salfi, S. Jacobs, R. P. Clement, and the Hepatitis C Intervention Therapy Group. 2000. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32:647-653.
14. Graci, J. D., and C. E. Cameron. 2002. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298:175-180.
15. Guo, J.-T., V. V. Bichko, and C. Seeger. 2001. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:8516-8523.
16. Gutfreund, K. S., and V. C. Bain. 2000. Chronic viral hepatitis C: management update. Can. Med. Assoc. J. 162:827-833.
17. Hamatake, R. K., Z. Hong, J. Y. N. Lau, and W. Zhong. Antiviral agents for hepatitis viruses, p, 235-277. In J.-H. J. Ou (ed,), Hepatitis viruses. Kluwer Academic Publishers, Norwell, Mass.
18. Huggins, J. W., R. K. Robbins, and P. G. Canonico. 1984. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob. Agents Chemother. 26:476-480.
19. Kim, W. R., R. S. Brown, Jr., N. A. Terrault, and H. El-Serag. 2002. Burden of liver disease in the United States: summary of a workshop. Hepatology 36:227-242.
20. Kirsi, J. J., J. A. North, P. A. McKernan, B. K. Murray, P. G. Canonico, J. W. Huggins, P. C. Srivastava, and R. K. Robbins. Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 24:353-361.
21. Lanford, R. E., D. Chavez, B. Guerra, J. Y. Lau, Z. Hong, K. M. Brasky, and B. Beames. 2001, Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75:8074-8081.
22. Lanford, R. E., B. Guerra, H. Lee, D. R. Averett, B. Pfeiffer, D. Chavez, L. Notvall, and C. Bigger. 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77:1092-1104.
23. Larrat, S., F. Stanke-Labesque, A. Plages, J.-P. Zarski, G. Bessard, and C. Souvignet. 2003. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 47:124-129.
24. Lau, J. Y. N., R. C. Tam, T. J. Lang, and Z. Hong. 2002. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:1002-1009.
25. Lindenbach, B. D., and C. M. Rice. 2001. Flaviviridae: the viruses and their replication, p. 991-1041. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, and B. Roizman (ed.) Fields virology, 4th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, Pa.
26. Lohmann, V., F. Körner, J.-O. Koch, U. Herian, L. Thielmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNA in a hepatoma cell line. Science 285:110-113.
27. Maag, D., C. Castro, Z. Hong, and C. E. Cameron. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:46094-46098.
28. Markland, W., T. J. McQuaid, J. Jain, and A. D. Kwong. 2000. Broadspectrum antiviral activity of the IMP dehydrogenase inhibitor VX-409: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44:859-866.
29. Neyts, J., A. Meerbach, P. McKenna, and E. De Clercq. 1996. Use of yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antivir. Res. 30:125-132.
30. Ouzounov, S., A. Mehta, R. A. Dwek, T. M. Block, and R. Jordan. 2002. The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus therapy. Antivir. Res. 55:425-435.
31. Prichard, M. N., K. R. Aseltine, and C. Shipman, Jr. 1993. MacSynergy II. Version 1.0. User's manual. University of Michigan, Ann Arbor.
32. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
33. Prichard, M. N., and C. Shipman, Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir. Ther. 1:9-20.
34. Scott, L. J., and C. M. Perry. 2002. Interferon-α-2b plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 62:507-556.
35. Severson, W. E., C. S. Schmaljohn, A. Javadian, and C. B. Jonsson. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77:481-488.
36. Stuyver, L. J., T. Whitaker, T. R. McBrayer, B. J. Hernandez-Santiago, S. Lostia, P. M. Tharnish, M. Ramesh, C. K. Chu, R. Jordan, J. Shi, S. Rachakonda, K. A. Watanabe, M. J. Otto, and R. F. Shinazi. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 47:244-254.
37. Tam, R. C., J. Y. N. Lau, and Z. Hong. 2002. Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 12:261-272.
38. Tsubota, A., N. Akuta, F. Suzuki, Y. Suzuki, T. Someya, M. Kobayashi, Y. Arase, S. Saitoh, K. Ikeda, and H. Kumada. 2002. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 45:33-42.
39. Weislow, O. S., R. Kiser, D. L. Fine, J. P. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
40. Wills, R. C., D. A. Carson, and J. E. Seegmiller. 1978. Adenosine kinase initiates the major source of ribavirin activation in a cultured human cell line. Proc. Natl. Acad. Sci. USA 75:3042-3044.
41. Zitzmann, N., A. S. Mehta, S. Carrouee, T. D. Butters, F. M. Platt, J. McCauley, B. S. Blumberg, R. A. Dwek, and T. M. Block. 1999. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C: implications for the development of broad spectrum antihepatitis virus agents. Proc. Natl. Acad. Sci. USA 96:11878-11882.